Use of chimeric antigen receptor modified cells to treat autoimmune disease
US11690874B2 · kind B2 · utility
1Cited by
0References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 12, 2019 |
| Grant date | Jul 4, 2023 |
| Priority date | — |
| Expiry date | Oct 5, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Embodiments of the present disclosure include a method for treating Systemic Lupus Erythematosus (SLE) using CD19 CAR T cells. The method includes administering to the human patient a pharmaceutically effective amount of a population of T cells of the human patient that express a chimeric antigen receptor (CAR) that comprises the amino acid sequence of, e.g., SEQ ID NO: 23.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.